We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Pact Coffee is an online seller of roasted coffee beans. All of Pact Coffee's beans are shipped within 7 days of roasting as this is when they taste the best. With the money invested, Pact look to develop new products and expand into 2 new european countries.      
days to go: Expired investment: £195,400
Celo is an app-based insurance provider designed to provide cheaper quotes, faster claims, and a pleasant user experience. We plan to offer insurance cover for motor vehicles, travel, health, and more. Like Monzo and Starling who are disrupting banking, Celo plans to disrupt the insurance industry.

Pitch Rated

39%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £142,840
Chip is a savings and investment portal. The company has over 250,000 registered users, processed over £165 million in savings, achieved Financial Conduct Authority (FSA) authorisation and launched Financial Services Compensation Scheme (FSCS) eligible interest accounts with market-leading rates. It aims to be the go to investment platform for the mobile generation that consists of 100 million customers and 30 trillion assets across Europe. Chip started with autosaving and seamless access to market-leading saving accounts. With its premium account ChipX, the company is venturing into investment funds, savings accounts, and pensions. It will use the investment to open up its investor community to new and existing investors to participate in this convertible round. It will also initiate discussions with venture capitalists to secure a follow up investment.
days to go: Expired investment: £11,403,860
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go: Expired investment: £5,083,686
The Honestly Good Smoothie Co. is a subscription box service that delivers 100% organic and pure pre-portioned smoothie components directly at your door-step. The company is known for its ready-to-blend frozen smoothie kits and has sold more than 8,000 smoothie kits so far. Since September 2018, the company has seen 60% customer retention with 25% of the customers spending above £500. Honestly Good has also been featured by BBC Radio, Bestfit Magazine, Forbes, and Nutribullet. With the proceeds, Honestly Good is planning to upscale its premises by introducing a developed, compostable and re-usable packaging system.
days to go: Expired investment: £264,990
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph